13F-HR filed by Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 18:15:53 UTC, with 30 holding rows worth $5,028,958,519.
- Accession
- 0001855655-26-000020
- Filer
- CIK 1855655
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 30 entries on the cover page, a total value of $5,028,958,519 stated on the cover page (in dollars after the unit check, H1), rows summing to $5,028,958,519 with VALUE read as dollars as filed, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 6,219,323 | $1,276,578,239 | dollars as filed | |
| GENMAB A/S | 372303206 | Ordinary Shares, nominal value DKK 1 per share | 14,136,472 | $504,318,639 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 10,778,665 | $437,613,799 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 4,457,450 | $396,846,774 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 2,695,977 | $307,718,815 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 3,772,885 | $221,166,519 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 2,493,507 | $207,684,198 | dollars as filed | |
| BELITE BIO INC | 07782B104 | CMN | 1,142,123 | $193,955,328 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 2,301,375 | $180,911,089 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 6,961,546 | $173,690,573 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 8,257,672 | $170,025,466 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 2,347,850 | $154,488,530 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 2,142,852 | $121,928,279 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 7,998,257 | $117,254,448 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 6,053,268 | $85,048,415 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 3,510,360 | $76,771,573 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 8,720,576 | $75,345,777 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 4,155,214 | $57,051,088 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 1,299,199 | $40,625,953 | dollars as filed | |
| ACHIEVE LIFE SCIENCES INC | 004468500 | COMMON STOCK | 4,951,856 | $40,060,515 | dollars as filed | |
| VERADERMICS INC | 922967104 | COMMON STOCK | 310,060 | $37,588,574 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 1,553,748 | $36,497,541 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 1,505,769 | $20,282,708 | dollars as filed | |
| KORSANA BIOSCIENCES INC | 23255M303 | COMMON STOCK | 613,914 | $19,645,248 | dollars as filed | |
| EDITAS MEDICINE INC | 28106W103 | COM | 7,575,140 | $19,468,110 | dollars as filed | |
| HEMAB THERAPEUTICS HLDGS INC | 423494103 | COM SHS | 629,347 | $19,409,061 | dollars as filed | |
| VOR BIOPHARMA INC | 929033207 | COMMON STOCK | 889,575 | $16,973,091 | dollars as filed | |
| KARDIGAN INC | 485925101 | CMN | 900,000 | $13,275,000 | dollars as filed | |
| TCGX ACQUISITION CORP | G8708J109 | COM | 300,000 | $3,753,000 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 808,176 | $2,982,169 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001855655-26-000020 | this filing | 2026-11-16 |